Skip to main content
SpringerLink
Log in

Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”

  • Letter to the Editor
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

The Original Article was published on 09 November 2020

The Original Research Article was published on 12 June 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Manning R, et al. Comment on “Market exclusivity for drugs with multiple orphan approvals (1983–2017) and associated budget impact in the US”. Pharmacoeconomics. 2020. https://doi.org/10.1007/s40273-020-00975-7.

    Article  PubMed  Google Scholar 

  2. Socal MP, Parasrampuria S, Anderson GF. Modifying the criteria for granting orphan drug market exclusivity. Value Health. 2020;23(11):1470–6. https://doi.org/10.1016/j.jval.2020.08.004.

    Article  PubMed  Google Scholar 

  3. Padula WV, Parasraumpuria S, Socal M, Conti RM, Anderson GF. Market exclusivity for drugs with multiple orphan approvals (1983–2017) and the associated budget impact in the US. Pharmacoeconomics. 2020;38:1115–21. https://doi.org/10.1007/s40273-020-00934-2.

    Article  PubMed  Google Scholar 

  4. Hakim A, Ross JS. Obstacles to the adoption of biosimilars for chronic diseases. J Am Med Assoc. 2017;317(21):2163–4.

    Article  Google Scholar 

  5. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–86.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical and Health Economics, School of Pharmacy, USC Schaeffer Center, University of Southern California, 635 Downey Way, Los Angeles, CA, 90089, USA

    William V. Padula

  2. Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA

    William V. Padula

  3. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    Sonal Parasrampuria, Mariana P. Socal & Gerard F. Anderson

  4. Institute for Health System Innovation and Policy, Boston University Questrom School of Business, Boston, MA, USA

    Rena M. Conti

Authors
  1. William V. Padula
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonal Parasrampuria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mariana P. Socal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rena M. Conti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gerard F. Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William V. Padula.

Ethics declarations

Funding

The authors were supported by an unrestricted grant from Arnold Ventures Foundation to Johns Hopkins University to conduct this investigation.

Conflicts of Interest/Competing Interests

William V. Padula, Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti, and Gerard F. Anderson have no conflicts of interest that are directly relevant to the content of this letter.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

Not applicable.

Code Availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Padula, W.V., Parasrampuria, S., Socal, M.P. et al. Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US”. PharmacoEconomics 38, 1375–1376 (2020). https://doi.org/10.1007/s40273-020-00973-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-020-00973-9

Search

Navigation